Browsing BioMed Central høstingsarkiv by Author "Vollan, Hans K M"

Now showing items 1-6 of 6

  • Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study 
    Tinholt, Mari; Viken, Marte K; Dahm, Anders E; Vollan, Hans K M; Sahlberg, Kristine K; Garred, Øystein; Børresen-Dale, Anne-Lise; Jacobsen, Anne F; Kristensen, Vessela; Bukholm, Ida; Kåresen, Rolf; Schlichting, Ellen; Skretting, Grethe; Lie, Benedicte A; Sandset, Per M; Iversen, Nina (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2014)
    Background The procoagulant state in cancer increases the thrombotic risk, but also supports tumor progression. To investigate the molecular mechanisms controlling cancer and hemostasis, we conducted a ...
  • Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer 
    Aure, Miriam R; Jernström, Sandra; Krohn, Marit; Vollan, Hans K M; Due, Eldri U; Rødland, Einar; Kåresen, Rolf; Ram, Prahlad; Lu, Yiling; Mills, Gordon B; Sahlberg, Kristine K; Børresen-Dale, Anne-Lise; Lingjærde, Ole C; Kristensen, Vessela N (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2015)
    Background The role played by microRNAs in the deregulation of protein expression in breast cancer is only partly understood. To gain insight, the combined effect of microRNA and mRNA expression on protein ...
  • Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome 
    Aure, Miriam R; Vitelli, Valeria; Jernström, Sandra; Kumar, Surendra; Krohn, Marit; Due, Eldri U; Haukaas, Tonje H; Leivonen, Suvi-Katri; Vollan, Hans K M; Lüders, Torben; Rødland, Einar; Vaske, Charles J; Zhao, Wei; Møller, Elen K; Nord, Silje; Giskeødegård, Guro F; Bathen, Tone F; Caldas, Carlos; Tramm, Trine; Alsner, Jan; Overgaard, Jens; Geisler, Jürgen; Bukholm, Ida R K; Naume, Bjørn; Schlichting, Ellen; Sauer, Torill; Mills, Gordon B; Kåresen, Rolf; Mælandsmo, Gunhild M; Lingjærde, Ole C; Frigessi, Arnoldo; Kristensen, Vessela N; Børresen-Dale, Anne-Lise; Sahlberg, Kristine K (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2017)
    Background Breast cancer is a heterogeneous disease at the clinical and molecular level. In this study we integrate classifications extracted from five different molecular levels in order to identify ...
  • Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status 
    Zhao, Xi; Rødland, Einar A; Sørlie, Therese; Vollan, Hans K M; Russnes, Hege G; Kristensen, Vessela N; Lingjærde, Ole C; Børresen-Dale, Anne-Lise (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2014)
  • Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations 
    Höglander, Elen K; Nord, Silje; Wedge, David C; Lingjærde, Ole C; Silwal-Pandit, Laxmi; Gythfeldt, Hedda v; Vollan, Hans K M; Fleischer, Thomas; Krohn, Marit; Schlitchting, Ellen; Borgen, Elin; Garred, Øystein; Holmen, Marit M; Wist, Erik; Naume, Bjørn; Van Loo, Peter; Børresen-Dale, Anne-Lise; Engebraaten, Olav; Kristensen, Vessela (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2018)
    Background Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) ...
  • Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF 
    Tinholt, Mari; Vollan, Hans K M; Sahlberg, Kristine K; Jernström, Sandra; Kaveh, Fatemeh; Lingjærde, Ole C; Kåresen, Rolf; Sauer, Torill; Kristensen, Vessela; Børresen-Dale, Anne-Lise; Sandset, Per M; Iversen, Nina (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2015)
    Introduction Hypercoagulability in malignancy increases the risk of thrombosis, but is also involved in cancer progression. Experimental studies suggest that tissue factor (TF) and tissue factor pathway ...